



# PHARMACOLOGY



**DONE BY : Volunteer**

	<b>MOA</b>	<b>INDICATION</b>	<b>PHARMACOKINATIC</b>	<b>ADVERSE EFFECT</b>
<b>Phenytoin</b>	Blocks voltage-gated Na <sup>+</sup> channels by binding to inactive state so slow recovery	<ul style="list-style-type: none"> <li>•Focal seizures</li> <li>•Tonic-clonic</li> <li>•NOT good for absence seizures</li> <li>•Status epilepticus (after BZD)</li> <li>•Antiarrhythmic/digoxin toxicity</li> </ul>	<ul style="list-style-type: none"> <li>•Induces CYP2C, CYP3A, UGT</li> <li>•“saturable enzyme metabolism”</li> <li>•Non-linear kinetics</li> <li>•Toxicity</li> </ul>	<ul style="list-style-type: none"> <li>•Nystagmus, ataxia</li> <li>•Diplopia, sedation</li> <li>•Gingival hyperplasia</li> <li>•Peripheral neuropathy/osteoporosis</li> <li>•Teratogenic</li> <li>•Blood: ↓ folate → Megaloblastic anemia</li> <li>•Drug-drug interactions: e.g., warfarin</li> </ul>
<b>Carbamazepine</b>	Blocks Na <sup>+</sup> channels	<ul style="list-style-type: none"> <li>•Focal seizures</li> <li>•Tonic-clonic</li> <li>•NOT good for absence seizures</li> <li>•Trigeminal neuralgia</li> <li>•Bipolar disorder</li> </ul>	<ul style="list-style-type: none"> <li>•Absorbed slowly</li> <li>•Long half-life (~ 30 hours)</li> <li>•Induces CYP2C, CYP3A, UGT</li> </ul>	<ul style="list-style-type: none"> <li>•Hyponatremia</li> <li>•Aplastic anemia</li> <li>•Teratogenic: Spina Bifida</li> <li>•Drowsiness; headache; dizziness; nausea</li> </ul>
<b>Valproic acid</b>	<ul style="list-style-type: none"> <li>•Blocks Na<sup>+</sup> channels</li> <li>•Blocks GABA transaminase (GABA-T)</li> <li>•Blocks T-type Calcium channels</li> </ul>	<ul style="list-style-type: none"> <li>•Focal seizures</li> <li>•Generalized seizures</li> <li>•Absence seizures</li> <li>•Bipolar disorder</li> </ul>	Inhibits CYP2C9, UGT, epoxide hydroxylase	<ul style="list-style-type: none"> <li>•Hepatotoxicity</li> <li>•Teratogenicity</li> <li>•CNS-related</li> </ul>
<b>Lamotrigine</b>	<ul style="list-style-type: none"> <li>•Blocks Na<sup>+</sup> channels</li> <li>•Blocks voltage-gated Ca<sup>++</sup> channels</li> </ul>	<ul style="list-style-type: none"> <li>•Focal seizures</li> <li>•Generalized seizures</li> <li>•Absence</li> <li>•Lennox-Gastaut syndrome</li> <li>•Bipolar disorder</li> </ul>	Metabolized by UGT	<ul style="list-style-type: none"> <li>•CNS-related side effects</li> <li>•Severe skin reaction (life-threatening)</li> </ul>
<b>Topiramate</b>	<ul style="list-style-type: none"> <li>•Blocks Na<sup>+</sup> channels</li> <li>•Blocks L-type Calcium channels</li> <li>•Carbonic anhydrase inhibitor</li> <li>•NMDA blocker</li> </ul>	<ul style="list-style-type: none"> <li>•Focal seizures</li> <li>•Generalized seizures</li> <li>•Migraine prevention</li> </ul>	Inhibits CYP2C9	<ul style="list-style-type: none"> <li>•Somnolence</li> <li>•Weight loss</li> <li>•Paresthesia</li> <li>•Renal stones</li> <li>•Oligohidrosis</li> <li>•hyperthermia</li> </ul>

<b>Zonisamide</b>	<ul style="list-style-type: none"> <li>•Blocks Na<sup>+</sup> channels</li> <li>•Blocks T-type Calcium channels</li> <li>•Limited carbonic anhydrase inhibitor</li> </ul>	<b>Focal seizures</b>	*****	<ul style="list-style-type: none"> <li>•CNS adverse effects</li> <li>•Nephrolithiasis</li> <li>•Oligohidrosis</li> <li>•Contraindicated in patients with sulfonamide hypersensitivity</li> </ul>
<b>Ethosuximide</b>	<b>Blocks T-type Calcium channels</b>	<b>Absence seizure only (Drug of choice)</b>	<b>Half life: 30 60 hrs</b>	*****
<b>Benzodiazepines Phenobarbital</b>	<b>Bind to GABAA receptors and enhance GABA binding</b> <input type="checkbox"/> facilitates Cl <sup>-</sup> entry <input type="checkbox"/> inhibitory	<ul style="list-style-type: none"> <li>•<i>Clonazepam</i> <input type="checkbox"/> adjunctive antiseizure therapy</li> <li>•<i>Diazepam</i> <input type="checkbox"/> status epilepticus (drug of choice)</li> </ul>	*****	*****
<b>Gabapentin Pregabalin</b>	<ul style="list-style-type: none"> <li>•Analog of GABA</li> <li>•It does NOT act at GABA receptor</li> <li>•MOA is unknown</li> </ul>	<ul style="list-style-type: none"> <li>•Adjunct therapy for focal seizures</li> <li>•Neuropathic pain, e.g., postherpetic neuralgia, diabetic neuropathy</li> </ul>	<ul style="list-style-type: none"> <li>•Secreted unchanged</li> <li>•Few drug interactions</li> <li>•Suitable for elderly</li> </ul>	<ul style="list-style-type: none"> <li>•Sedation</li> <li>•Euphoria</li> </ul>
<b>Felbamate</b>	<ul style="list-style-type: none"> <li>•Blocks voltage-gated Na<sup>+</sup> channels</li> <li>•Blocks NMDA receptors</li> <li>•Blocks Ca<sup>++</sup> channels</li> <li>•Potentiates GABA</li> </ul>	<ul style="list-style-type: none"> <li>•Reserved for refractory epilepsy</li> <li>•Lennox-Gastaut syndrome</li> </ul>	<ul style="list-style-type: none"> <li>•Inhibits CYP2C19</li> <li>•Induces CYP3A4</li> </ul>	<ul style="list-style-type: none"> <li>•Aplastic anemia</li> <li>•Hepatic failure</li> <li>•Dangerous drug</li> </ul>
<b>Ezogabine</b>	<b>Open voltage gated M type potassium channels <input type="checkbox"/> stabilizing resting membrane potential</b>	*****	<b>No drug interactions at low doses</b>	<ul style="list-style-type: none"> <li>•Urinary retention</li> <li>•QT interval prolongation</li> <li>•Blue skin discoloration</li> <li>•Retinal abnormalities</li> </ul>

<b>Levetiracetam</b>	unknown	<ul style="list-style-type: none"> <li>•Focal (simple and complex) seizures</li> <li>•Adjunct therapy for generalized seizures</li> </ul>	*****	<ul style="list-style-type: none"> <li>•Dizziness</li> <li>•somnolence</li> </ul>
----------------------	---------	---	-------	---

### Mechanism of action

**1-Na<sup>+</sup>-channels inhibitors** •Phenytoin •Carbamazepine •Oxcarbazepine •Valproic acid •Lamotrigine •Topiramate

**2-Ca<sup>++</sup>-channels inhibitors** •Ethosuximide •Lamotrigine •Valproic acid

**3-↑ GABAergic transmission** •Benzodiazepines •Phenobarbital •Valproic acid •Gabapentin?, Pregabalin? •Felbamate

**4-NMDA receptor blockers:** Felbamate, topiramate

**5-AMPA receptor blockers:** Perampanel

**6-H-current modulators:** Gabapentin, lamotrigine

**7-Carbonic anhydrase inhibitors:** Topiramate, zonisamide

**8-Neuronal potassium channel (KCNQ[Kv7]) opener** Ezogabine

**Teratogenic :** 1- Phenytoin 2- Carbamazepine 3- Valproic acid

**Focal seizures :** 1- Phenytoin 2- Carbamazepine 3- Valproic acid 4- Lamotrigine 5- Topiramate 6- Zonisamide 7- Levetiracetam

**Tonic-clonic :** 1- Phenytoin 2- Carbamazepine

**Status epilepticus :** 1- Phenytoin

**Lennox-Gastaut syndrome :** 1- Lamotrigine 2- Felbamate

**absence seizures :** 1- Valproic acid 2- Lamotrigine 3- Ethosuximide 4- Gabapentin+Pregabalin(adjusant)

**Generalized seizures :** 1- Valproic acid 2- Lamotrigine 3- Topiramate 4- Levetiracetam

**Trigeminal neuralgia :** 1- Carbamazepine

**Bipolar disorder :** 1- Carbamazepine 2- Valproic acid 3- Valproic acid

**Migraine prevention : 1- Topiramate**

**Induce hepatic metabolism :1- Phenytoin 2- Carbamazepine**

**Inhibit hepatic metabolism : 1-Valproic acid 2- Topiramate 3- Felbamate**

**Aplastic anemia : 1- Carbamazepine 2- Felbamate**

**Hyponatremia : 1- Carbamazepine**

**Hepatotoxicity : 1- Valproic acid 2- Felbamate**

**Severe skin reaction (life-threatening) :1- Lamotrigine**

**Somnolence : 1-Topiramate 2- Levetiracetam**

**Weight loss : 1- Topiramate**

**Paresthesia :1- Topiramate**

**Renal stones: 1- Topiramate 2- Zonisamide**

**Oligohidrosis: 1- Topiramate 2- Zonisamide**

**Hyperthermia: 1- Topiramate**

**•Urinary retention 1-Ezogabine**

**•QT interval prolongation 1-Ezogabine**

**•Blue skin discoloration 1-Ezogabine**

**•Retinal abnormalities 1- Ezogabine**

### **EXTRA NOTE**

- **Fosphenytoin Is prodrug of Phenytoin**
- **Oxcarbazepine Prodrug to Carbamazepine with Less side effects**
- **Other preparation of Valproic acid 1-Sodium valproate 2-Divalproex sodium**
- **Zonisamide has sulfonamide hypersensitivity**
- **Gabapentin + Pregabalin use for neuropathic pain**